Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEMADEX vs ENTEREG
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Selective 5-HT4 receptor agonist; enhances gastrointestinal motility by increasing peristalsis and accelerating colonic transit.
Edema associated with heart failure, hepatic cirrhosis, and renal disease,Hypertension (off-label)
FDA-approved for the treatment of chronic idiopathic constipation in adults
Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.
Adults: 12 mg orally twice daily for up to 15 days, initiated within 30 minutes prior to surgery and continued postoperatively.
The terminal elimination half-life is approximately 4 hours (range 2-8 hours) in patients with normal renal function. In renal impairment (creatinine clearance <30 m L/min), half-life is prolonged to 10-12 hours due to reduced renal clearance. In hepatic cirrhosis, half-life may be extended to 8-9 hours due to decreased metabolism.
Terminal half-life is approximately 10–17 hours in healthy subjects. Clinically, the half-life may be prolonged in severe hepatic impairment but is not significantly altered in renal impairment.
Primarily hepatic via CYP450 enzymes, with minimal renal clearance.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4); also involves CYP2D6 and CYP2C9 to a lesser extent.
Approximately 50% of the absorbed dose is excreted unchanged in the urine via glomerular filtration and active tubular secretion. The remainder undergoes hepatic metabolism to glucuronide conjugates and minor oxidative metabolites, with biliary excretion of metabolites (about 30-40% of the dose) eliminated in feces. Renal clearance is the primary route for the parent drug.
Primarily hepatobiliary excretion; unchanged drug and major metabolite (alvimopan) undergo extensive biliary elimination with fecal excretion accounting for >90% of total elimination. Renal excretion is minimal (<5% as unchanged drug).
Torsemide (DEMADEX) is extensively bound to plasma proteins, primarily albumin, with a protein binding of >99%.
Approximately 80–90% bound to plasma proteins, primarily albumin.
The apparent volume of distribution (Vd) is approximately 0.16 L/kg (range 0.12–0.20 L/kg), indicating distribution primarily within extracellular fluid. Vd is increased in conditions with expanded extracellular volume (e.g., heart failure, cirrhosis, nephrotic syndrome).
Volume of distribution is about 30 L (approximately 0.4 L/kg), indicating distribution into extracellular fluid and tissues.
Oral bioavailability is approximately 80–90%, with minimal first-pass metabolism. Absorption is rapid and not significantly affected by food.
Oral bioavailability is approximately 6–10% due to extensive first-pass metabolism; the drug is administered orally for local gastrointestinal activity.
GFR <20 m L/min/1.73 m²: Use with caution; may require dose reduction or discontinuation due to accumulation. GFR 20-50: No adjustment needed. GFR >50: No adjustment.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) or dialysis.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% or extend interval. Child-Pugh C: Avoid use or reduce dose by 75%.
No dose adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Caution in severe hepatic impairment (Child-Pugh C); no specific dose recommendation.
Neonates and infants: 0.1-0.2 mg/kg/dose IV/IM once daily. Children: Oral: 0.5-1 mg/kg once daily; IV/IM: 0.1-0.2 mg/kg/dose once daily. Maximum: 5 mg/day.
Not FDA-approved for pediatric patients; safety and efficacy not established.
Start at lower end of dose range (2.5-5 mg orally once daily); titrate slowly due to increased sensitivity and renal impairment risk.
No specific dose adjustment; use with caution due to potential increased sensitivity and renal function decline. Monitor for adverse effects.
None.
No FDA boxed warning.
Hypotension and volume depletion,Electrolyte imbalances (hypokalemia, hyponatremia, hypochloremia),Ototoxicity (especially with rapid IV administration or high doses),Hyperuricemia,Sulfonamide allergy cross-reactivity
May cause diarrhea, leading to electrolyte disturbances or hypovolemia,Use with caution in patients with severe renal impairment,Avoid use in patients with a history of mechanical gastrointestinal obstruction, perforation, or severe inflammatory bowel disease
Anuria,Severe electrolyte depletion,Hypersensitivity to sulfonamides or bumetanide (Demadex is a sulfonamide derivative)
Hypersensitivity to prucalopride or any excipients,Renal impairment requiring dialysis,Intestinal obstruction or perforation
Avoid excessive licorice intake (glycyrrhizin) as it can exacerbate hypokalemia. Limit sodium-rich foods (processed foods, canned soups) to enhance diuretic effect and control edema. Increase potassium-rich foods (bananas, oranges, potatoes) unless on a potassium-sparing medication. Avoid grapefruit juice as it may affect metabolism.
No specific food interactions reported. However, as ENTEREG is administered in a hospital setting, patients should follow the prescribed diet (typically clear liquids advancing to regular diet as tolerated postoperatively). Avoid grapefruit juice as it may affect drug metabolism via CYP3A4 (though not specifically studied, caution is advised).
DEMADEX (torsemide) is a loop diuretic. Human data are limited. In animal studies, high doses caused fetal resorptions and maternal toxicity. First trimester: insufficient human data; avoid unless benefit outweighs risk. Second/third trimester: risk of fetal oligohydramnios, renal impairment, and hypovolemia; use only if clearly needed.
No human data; animal studies at doses up to 10 mg/kg/day in rats and rabbits showed no teratogenicity at exposures lower than human dose; risk cannot be excluded due to lack of adequate human studies.
Torsemide is excreted in breast milk in small amounts; M/P ratio not reported. Due to potential for diuresis, electrolyte imbalance, and allergic reactions in the infant, caution is recommended. Alternative diuretics with more safety data are preferred.
No data on presence in human milk; caution advised; M/P ratio unknown.
Dosing may need adjustment due to increased plasma volume and GFR in pregnancy. Start at lowest effective dose. Monitor diuretic response and electrolyte balance; dose titration may be required. Postpartum, drug elimination may return to prepregnancy kinetics.
No pharmacokinetic studies in pregnancy; dose adjustment not required based on available data.
DEMADEX (torsemide) is a loop diuretic with high bioavailability (80-100%) and a longer half-life (3-4 hours) than furosemide, allowing once-daily dosing. It is primarily metabolized by CYP2C9, so caution is needed with CYP2C9 inhibitors like amiodarone. Monitor for ototoxicity at high doses or rapid infusion. Hypokalemia risk persists; consider potassium supplementation or aldosterone antagonist. Use cautiously in sulfonamide allergy due to potential cross-sensitivity.
ENTEREG (alvimopan) is a peripherally acting mu-opioid receptor antagonist indicated to accelerate postoperative recovery of GI function after bowel resection surgery. It does not cross the blood-brain barrier, so it does not reverse opioid analgesia. Use is restricted to hospitalized patients; it should not be used for more than 7 days. Contraindicated in patients who have taken therapeutic doses of opioids for >7 consecutive days immediately prior to initiation, as it may precipitate opioid withdrawal. Monitor for GI adverse effects such as nausea, vomiting, and abdominal pain.
Take DEMADEX exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Weigh yourself daily and report sudden weight gain or loss of more than 2-3 pounds in a day.,Avoid alcohol and beverages containing caffeine as they may increase dehydration.,Do not take DEMADEX with licorice (which can worsen hypokalemia) or with high-sodium antacids.,Report signs of hearing loss, ringing in the ears, dizziness, or muscle cramps immediately.,Stand up slowly to prevent dizziness from low blood pressure.,Monitor for signs of dehydration: dry mouth, thirst, infrequent urination.
Take ENTEREG exactly as prescribed; do not take more than the recommended dose.,This medication is used only in the hospital after bowel surgery to help your bowels start working again.,It does not reduce pain or interfere with your pain medication.,Report any severe abdominal pain, nausea, vomiting, or diarrhea to your healthcare provider.,Do not take this medication if you have recently taken opioid pain medications for more than 7 days in a row.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEMADEX vs ENTEREG, answered by our medical review team.
DEMADEX is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. ENTEREG is a Peripheral Opioid Antagonist that works by Selective 5-HT4 receptor agonist; enhances gastrointestinal motility by increasing peristalsis and accelerating colonic transit.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEMADEX and ENTEREG depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEMADEX is: Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.. The standard adult dose of ENTEREG is: Adults: 12 mg orally twice daily for up to 15 days, initiated within 30 minutes prior to surgery and continued postoperatively.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEMADEX and ENTEREG in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEMADEX is classified as Category C. DEMADEX (torsemide) is a loop diuretic. Human data are limited. In animal studies, high doses caused fetal resorptions and maternal toxicity. First trimester: insufficient human da. ENTEREG is classified as Category C. No human data; animal studies at doses up to 10 mg/kg/day in rats and rabbits showed no teratogenicity at exposures lower than human dose; risk cannot be excluded due to lack of ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.